Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2019

01-08-2019 | Prostate Cancer | Research Article

Identification a novel set of 6 differential expressed genes in prostate cancer that can potentially predict biochemical recurrence after curative surgery

Authors: F. Li, J.-P. Ji, Y. Xu, R.-L. Liu

Published in: Clinical and Translational Oncology | Issue 8/2019

Login to get access

Abstract

Purpose

Approximately, 30% patients after radical prostatectomy (RP) will undergo post-operative biochemical recurrence (BCR). Present stratification method by TNM staging and Gleason score was not adequate to screen high-risk patients. In this study, we intended to identify a novel set of differentially expressed gene (DEG) signature that can predict BCR after RP.

Materials/patients

358 patients after RP with follow-up data were extracted from The Cancer Genome Atlas (TCGA), among which 61 patients had undergone BCR. Key DEGs were confirmed by the intersection of GSE35988 and TCGA_PCa dataset, and their gene expression data were also extracted from TCGA_PCa dataset. Kaplan–Meier plot and Cox proportion hazard regression model were applied to assess the relationship between risk score and survival outcome (BCR).

Results

310 DEGs were confirmed in two prostate cancer dataset. 6 DEGs (SMIM22, NINL, NRG2, TOP2A, REPS2, and TPCN2) were selected to construct a risk score formula. The risk score was a powerful predictive factor independent of TNM stage (HR 3.045, 95% CI 1.655–5.602, p < 0.001).

Conclusion

In this study, a novel 6-gene signature with robust predictive ability on post-operative BCR was constructed and 4 genes (SMIM22, NRG2, NINL and TPCN2) in the 6-gene signature were not reported to be associated with prostate cancer.
Literature
1.
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42.CrossRefPubMed
2.
Li D, Lv H, Hao X, et al. Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis. Cancer Manag Res. 2018;10:3125–39.CrossRefPubMedPubMedCentral
3.
Huang W, Su X, Yan W, et al. Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer. Prostate. 2018;78:1248–61.CrossRefPubMed
4.
Zheng Y, Gao Y, Li X, et al. Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-beta A. Onco Targets Ther. 2018;11:4965–77.CrossRefPubMedPubMedCentral
5.
Albala D, Kemeter MJ, Febbo PG, et al. Health economic impact and prospective clinical utility of oncotype DX(R) Genomic Prostate Score. Rev Urol. 2016;18:123–32.PubMedPubMedCentral
6.
Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245–55.CrossRefPubMedPubMedCentral
7.
Karnes RJ, Choeurng V, Ross AE, et al. Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathologic features. Eur Urol. 2018;73:168–75.CrossRefPubMed
8.
Jiang Y, Mei W, Gu Y, et al. Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence. Mol Oncol. 2018;12:1559–78.CrossRefPubMedPubMedCentral
9.
10.
Ross AE, D’Amico AV, Freedland SJ. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis. 2016;19:1–6.CrossRefPubMed
11.
12.
Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–102.CrossRefPubMedPubMedCentral
13.
14.
Li B, Ruotti V, Stewart RM, et al. RNA-Seq gene expression estimation with read mapping uncertainty. Bioinformatics. 2010;26:493–500.CrossRefPubMed
15.
Thompson IM, Andriole GL, Blumenstein B, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2003.
16.
Arredouani MS, Lu B, Bhasin M, et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res. 2009;15:5794–802.CrossRefPubMedPubMedCentral
17.
Reimand J, Arak T, Adler P, et al. g:profiler—a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 2016;44:W83–9.CrossRefPubMedPubMedCentral
18.
Huang TB, Dong CP, Zhou GC, et al. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival. Int Urol Nephrol. 2017;49:825–35.CrossRefPubMed
19.
Pathan M, Keerthikumar S, Ang CS, et al. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597–601.CrossRefPubMed
20.
Molinari C, Matteucci F, Caroli P, et al. Biomarkers and molecular imaging as predictors of response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2015;14:227–38.CrossRefPubMed
21.
Polycarpou-Schwarz M, Gross M, Mestdagh P, et al. The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. Oncogene. 2018;37:4750–68.CrossRefPubMed
22.
Ring HZ, Chang H, Guilbot A, et al. The human neuregulin-2 (NRG2) gene: cloning, mapping and evaluation as a candidate for the autosomal recessive form of Charcot-Marie-Tooth disease linked to 5q. Hum Genet. 1999;104:326–32.CrossRefPubMed
23.
Dunn M, Sinha P, Campbell R, et al. Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J Pathol. 2004;203:672–80.CrossRefPubMed
24.
25.
Nguyen ON, Grimm C, Schneider LS, et al. Two-pore channel function is crucial for the migration of invasive cancer cells. Cancer Res. 2017;77:1427–38.CrossRefPubMed
26.
Oosterhoff JK, Penninkhof F, Brinkmann AO, et al. REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells. Oncogene. 2003;22:2920–5.CrossRefPubMed
27.
Penninkhof F, Grootegoed JA, Blok LJ. Identification of REPS2 as a putative modulator of NF-kappaB activity in prostate cancer cells. Oncogene. 2004;23:5607–15.CrossRefPubMed
28.
Oosterhoff JK, Kuhne LC, Grootegoed JA, et al. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2. Int J Cancer. 2005;113:561–7.CrossRefPubMed
29.
Badway JA, Baleja JD. Reps2: a cellular signaling and molecular trafficking nexus. Int J Biochem Cell Biol. 2011;43:1660–3.CrossRefPubMed
30.
Schaefer-Klein JL, Murphy SJ, Johnson SH, et al. Topoisomerase 2 alpha cooperates with androgen receptor to contribute to prostate cancer progression. PLoS ONE. 2015;10:e0142327.CrossRefPubMedPubMedCentral
Metadata
Title
Identification a novel set of 6 differential expressed genes in prostate cancer that can potentially predict biochemical recurrence after curative surgery
Authors
F. Li
J.-P. Ji
Y. Xu
R.-L. Liu
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-02029-z

Other articles of this Issue 8/2019

Clinical and Translational Oncology 8/2019 Go to the issue

Research Article

Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma

Research Article

Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study

Correspondence

Common misconceptions in the prognostic evaluation of clinically stable patients with febrile neutropenia and solid tumors

Research Article

Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1

Research Article

Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes

Review Article

The RANK–RANKL axis: an opportunity for drug repurposing in cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits